Vacina experimental de mRNA demonstra proteção contra múltiplos vírus Ebola

22 de maio de 2026

Reportado por IA

Uma vacina experimental de mRNA demonstrou eficácia contra três cepas do vírus Ebola em testes com roedores. A vacina tem como alvo os vírus Zaire, Sudão e Bundibugyo. Os pesquisadores a desenvolveram em meio a um surto contínuo do vírus Bundibugyo na África.

Yanfeng Yao e seus colegas do Instituto de Virologia de Wuhan criaram a vacina combinando sequências de mRNA para glicoproteínas de cada vírus, juntamente com uma nucleoproteína compartilhada dentro de uma nanopartícula lipídica. Nos testes, camundongos imunizados obtiveram proteção completa contra os vírus Zaire e Sudão e forte proteção contra o Bundibugyo. Hamsters também receberam proteção total contra a exposição ao vírus Sudão.

AI-designed “pan-sarbecovirus” vaccine candidate reports early safety and immune-response signals in first human trial

05 de junho de 2026 Reportado por IA Imagem gerada por IA Verificado

A needle-free, DNA-based vaccine candidate designed using machine-learning methods has completed a first-in-human Phase 1 study in the UK, with researchers reporting it was well tolerated and induced immune responses against multiple viruses in the sarbecovirus group, which includes SARS-CoV, SARS-CoV-2 and related bat coronaviruses.

Engineered phages redirect vaccine immunity to eradicate tumors in mice

Researchers have used genetically modified phages to harness pre-existing vaccine immunity and destroy cancer cells in mice. The approach eradicated tumors in 44 percent of treated animals with no recurrence after a year.

Moderna advances hantavirus vaccine after cruise ship deaths

11 de maio de 2026 Reportado por IA

Moderna confirmed ongoing work on an mRNA vaccine for hantavirus following a deadly outbreak on a Dutch cruise ship. The effort, in partnership with Korea University, began in 2023 and shows promise but remains years from completion.

Asia

Philippines remains free of Ebola, DOH says

Africa

Scientists warn of bat coronavirus risk in East Africa

Africa

WHO warns of Ebola spread risk as Kenya activates emergency response measures

Virus injection halts pancreatic tumor growth in trial

A genetically engineered virus has stopped pancreatic tumors from growing in three patients in an early US clinical trial. The results come from a safety study led by researchers at the University of Minnesota.

Scripps researchers reveal HIV and Ebola weak spots using nanodiscs

12 de abril de 2026 Reportado por IA

Scientists at Scripps Research have developed a nanodisc platform that mimics viral membranes, uncovering hidden interactions in HIV and Ebola proteins that traditional methods miss. The technology allows for more accurate study of antibody responses, potentially accelerating vaccine development. The findings appear in Nature Communications.

sábado, 13 de junho de 2026, 13:47h